Scientific Programme
Scientific
Programme
November 6, 2025 -Thursday |
|
|---|---|
| 18.00-18.20 | Welcome |
| 18.20-18.50 | Opening Lecture One Health in the Perspective of a Toxicologist Félix Carvalho (Portugal) |
| 19.00 | Opening Reception |
November 7, 2025 -Friday |
|
| 09.00-09.30 | Plenary Lecture Toxicological Consideration and Risk Assessment of Drug Impurities Biljana Antoijevic (Serbia) |
SESSION 1: Advances in Food Safety and Risk Assessment: Emerging Challenges and Solutions |
|
| 09.30-10.00 | Toxic metals in food and their emerging role as risk factors in hormone-related reproductive cancers Aleksandra Buha (Serbia) |
| 10.00-10.30 | Food Safety Risk Assessment in Türkiye Serap Hancı (Türkiye) |
| 10.30-11.00 | Challenges of the Risk Assessment of Dietary Microplastics María-Carmen Rubio-Armendáriz (Canary Islands, Spain) |
| 11.00-11.15 | Coffee Break |
SESSION 2: Epigenetic Mechanisms in Toxicology |
|
| 11.15-11.45 | Epigenetic biomarkers for chemical hazard assessment Joëlle Rüegg (Sweden) |
| 11.45-12.15 | AHR-mediated m6A RNA methylation contributes to PM2.5-induced cardiac defects Tao Chen (China) |
| 12.15-12.45 | Role of epigenetic modifications in the toxicity mechanisms of Fusarium-induced mycotoxins Ecem Fatma Karaman (Türkiye) |
| 12.45-13.30 | Lunch Break |
SESSION 3: New Approaches to In Vitro Efficacy/Toxicity Assessment – Advantages and Limitations |
|
| 13.30-14.00 | New air-liquid interface (ALI) system approach for drug efficacy/toxicity testing Merve Güdül Bacanlı (Türkiye) |
| 14.00-14.30 | Challenges in implementing New Approaches Methodologies in the risk assessment of nanomaterials Ivana Vinković Vrček (Croatia) |
| 14.30-15.00 | Organoid models to test drug safety and efficacy Esra Erdal (Türkiye) |
| 15.00-15.30 | Advancements of in vitro methods for inhalation toxicity towards next generation risk assessment Tommaso Serchi (Luxembourg) |
SESSION 4: Cutting-edge Advances in NAMs – What’s New and What’s Next |
|
| 15.30-15.50 | Advancing immunotoxicology: NAMs for immunosuppression and developmental immunotoxicity Emanuela Corsini (Italy) |
| 15.50-16.10 | Advancing ocular safety: insights into the new OECD guideline Helena Kandarova (Slovakia) |
| 16.10-16.30 | NAMs in cosmetics: the future of safety and innovation Zehra Sarıgöl-Kılıç (USA) |
| 16.30-16.50 | Computational and predictive analysis in toxicology Sanin Haveric (Bosnia and Herzegovina) |
| 16.50-17.15 | Coffee Break |
SESSION 5: Safety in Psychotropic Medications Treatment |
|
| 17.15-17.45 | Monitoring the safety and tolerability of antipsychotic drug treatment Christoph Hiemke (Germany) |
| 17.45-18.15 | Comprehensive overview on intoxications with psychotropic drugs Fredrik C. Kugelberg (Sweden) |
| 18.15-18.45 | Pharmacokinetic genes variations and response to treatment: the examples of risperidone, aripiprazole and clozapine Eap-Bin Chin (Switzerland) |
| 18.45-19.15 | The impact of pharmacodynamic gene variations on adverse drug reactions in antidepressant treatment Sinan Süzen (Türkiye) |
November 8, 2025 -Saturday |
|
| 09.00-09.30 | Plenary Lecture Toxicology Risk Management through Interdisciplinary Approaches to Meet ESG Requirements and Sustainability Challenges Salmaan Hussain B Inayat Hussain (Malaysia) |
| 09.30-09.45 | Coffee Break |
SESSION 6: The Importance of Genotoxicity Tests in the Biomonitoring of Chemical Hazards in Occupational Settings |
|
| 09.45-10.10 | The comet assay in human biomonitoring Andrew Collins (Norway) |
| 10.10-10.35 | Alkaline Comet and Micronucleus Cytome Assay – The use of the Methods and Their Perspectives through the results of the HCOMET, HUMNAP, EDIAQI, AND BIOMOLTOX Projects Mirta Milic (Croatia) |
| 10.35-11.00 | Steel Industry in Bosnia and Herzegovina – Human Biomonitoring in Exposed Population Anja Haveric (Bosnia and Herzegovina) |
| 11.00-11.25 | Genotoxicity biomarkers in occupational exposure to hazardous compounds in Portugal: Lessons learned on formaldehyde, antineoplastics and volatile organic compounds Carina Ladeira (Portugal) |
| 11.25-11.50 | Occupational exposure to mineral fibers – biomarkers of exposure, effect and susceptibility Maria Dusinska (Slovakia/Norway) |
| 12.00-13.30 | Lunch Break |
SESSION 7: Microplastics – State of the Science and the Impacts on Human Health |
|
| 13.30-13.50 | Understanding microplastics and human health concerns Neslihan Aygun Kocabaş (Belgium) |
| 13.50-14.10 | Challenges of microplastics research in risk assessment: Ensuring generation of quality data Erik Rushton (Netherlands) |
| 14.10-14.30 | Plastic chemical additives: determining human risk from microplastic exposure John Norman (USA) |
| 14.30-14.50 | Microplastics: unfolding consequences Marijana Curcic (Serbia) |
SESSION 8: Transporters in Toxicology – Unraveling Mechanisms of Xenobiotic Exposure, Metabolic Dysfunction, and Reproductive Health |
|
| 15.00-15.40 | Fetoplacental toxicity and mycoestrogens at the placental barrier Lauren M. Aleksunes (USA) |
| 15.40-16.20 | Multidrug resistance protein 4 dysfunction drives hepatic steatosis and metabolic dysregulation: Integrated in vivo and in vitro insights José E. Manautou (USA) |
| 16.20-17.00 | Integrating drug development tools to predict per- and polyfluoroalkyl (PFAS)-transporter interactions and disposition to human liver Angela L. Slitt (USA) |
| 20.00 | Gala Dinner |
November 9, 2025 -Sunday |
|
| 09.00-09.30 | Plenary Lecture Mode of action-based refined risk assessment for direct and indirect genotoxic carcinogens Andrea Hartwig (Germany) |
SESSION 9: Advancements in Understanding the Mechanisms of Organ-Specific Toxicity Induced by Chemicals and Drugs |
|
| 09.30-10.00 | New insight into molecular targets and early key events in genotoxicity and renal carcinogenicity of the mycotoxin ochratoxin A Johannes Borchers (Germany) |
| 10.00-10.30 | Towards understanding the mechanism of methanol-induced optic nerve damage by leveraging human data Hilmi Orhan (Türkiye) |
| 10.30-11.00 | Particle-induced acute phase response as a mechanism-of-action of particle-induced cardiovascular disease Ulla Vogel (Denmark) |
| 11.00-11.30 | Human in vitro models for the detection and understanding of chemical-induced nephrotoxicity Paul Jennings (The Netherlands) |
| 11.30-11.45 | Coffee Break |
SESSION 10: European and National Regulation on Medical Devices – Challenges and Opportunities for Toxicologists |
|
| 11.45-12.15 | Medical devices made of substances: challenges on definitions for classification and biosafety assessment Marco Racchi (Italy) |
| 12.15-12.45 | Toxicological challenges for industry in the application of MDR 745/2017 Nina Eriksen (Denmark) |
| 12.45-13.15 | Methodological aspects for biosafety compliance in medical devices Emanuela Testai (Italy) |
| 13.15-13.45 | Toxicological risk assessment for extractables/leachables in pharmaceuticals and medical devices Ahmet Aydın (Türkiye) |
